The benefit of heart rate (HR) reduction in patients with stable coronary artery disease is well demonstrated for symptom prevention and relief, and benefits on outcomes are being actively investigated. We aimed to quantify the reduction in resting HR induced by 5 antianginal drugs frequently used for symptom prevention (diltiazem, verapamil, atenolol, metoprolol, and ivabradine) in stable angina pectoris. We identified studies published between 1966 and 2007 in PubMed, Embase, and the Cochrane database and reviewed the bibliographies to locate additional studies. Eligible studies were double-blind, randomized, placebo-controlled trials in patients with stable angina. Trials were combined using weighted mean difference and fixed-effect model meta-analysis. The main outcome measure was resting HR at the study end. For diltiazem, resting HR reduction versus placebo ranged from 20.08 beats per minute (bpm) [95% confidence interval (CI) 21.5 to +1.4] for 120 mg/d to 28.0 bpm (95% CI, 211.1 to 25.0) with 360 mg/d. For sustained-release diltiazem, there was a reduction in resting HR of 24.5 bpm (95% CI, 26.4 to 22.5), with no dose-response relationship (heterogeneity P = 0.62). Resting HR reductions for the other agents were 23.2 bpm (95% CI, 25.1 to 21.3) for verapamil (with no doseresponse relationship, heterogeneity P = 0.87); 219.0 bpm (95% CI, 220.4 to 217.6) for atenolol; 213.2 bpm (95% CI, 214.7 to 211.7) for metoprolol (with greater reductions for 150 mg/d and long-acting 190 mg/d); and between 29.3 bpm (95% CI, 213.8 to 24.8) and 219.6 bpm (95% CI, 223.8 to 215.4) for ivabradine. Ivabradine, atenolol, and metoprolol give similar reductions in resting HR (210 to 220 bpm), whereas verapamil and diltiazem produce only marginal reductions (,10 bpm).
INTRODUCTION
There is an inverse relationship between resting heart rate (HR) and survival in the general population [1] [2] [3] and, more specifically, for patients with coronary artery disease (CAD). 4, 5 As HR increases, the tendency to induce or exacerbate myocardial ischemia and angina also increases. This pathophysiology results from increases in oxygen demand, due to an increase in cardiac workload, and decreases myocardial perfusion, 1 due to a shortening of diastolic duration, 6 both directly related to HR. The benefits of HR reduction in patients with CAD have been well demonstrated for the prevention of ischemia and the relief of angina pectoris, which is the most commonly reported symptom of CAD. [7] [8] [9] Experimental and clinical data indicate that the basis of this benefit combines reduction in myocardial oxygen demand 10, 11 and increase in myocardial perfusion and oxygen supply. 12 Although these observations suggest mechanisms that might underlie the observed relationship of HR with survival, HR reduction may have other effects, for example, on the development of atherosclerosis [13] [14] [15] and on plaque rupture, 16 which may further favor survival and lower the frequency of major adverse cardiovascular events.
The benefits of pharmacological HR reduction on outcomes in stable CAD have been postulated and are now under active investigation. The recent results of the BEAUTIFUL (morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction) study confirmed that resting HR $70 beats per minute (bpm) is an independent risk factor in patients with stable CAD and left ventricular systolic dysfunction. 17 HR lowering with ivabradine in patients with CAD and HR $70 bpm significantly reduced fatal and nonfatal myocardial infarction (MI) and need for coronary revascularization 18 ; among BEAUTIFUL subjects with angina, HR slowing with ivabradine induced a reduction in cardiovascular mortality and hospitalization for MI or HF. 19 These data indicate the importance of HR control in the management of stable CAD for risk assessment and to guide optimal therapy. Therefore, because antianginal and anti-ischemic drugs are among the agents most often prescribed for patients with CAD, it is important to understand their HR-modulating effects, as one of the criteria on which to base the selection of specific antianginal agents for individual patients.
We therefore performed a meta-analysis of prospective, randomized, placebo-controlled clinical trials to determine the magnitude of the HR-lowering effect of antianginal drugs in patients with stable angina pectoris.
METHODS
The study protocol was developed prospectively and prespecified the objectives of the meta-analysis, as well as the search strategy, study eligibility criteria, methods of data extraction, and statistical analysis.
Selection of randomized trials
We selected prospective, randomized, double-blind, placebo-controlled trials assessing diltiazem, verapamil, atenolol, metoprolol, or ivabradine (independently of whether additional active comparators were employed), provided they specifically enrolled patients with chronic stable angina as their study population. These trials were identified using a 2-level search strategy. First, public domain databases, including PubMed, Embase, and the Cochrane Central Register of Controlled Trials, were searched electronically using dedicated search engines. Second, relevant studies were identified through a manual search of secondary sources, including bibliographic references cited in the identified articles and a search of reviews, commentaries, and conference proceedings. The PubMed database was searched up to July 2007. MeSH keywords included ''diltiazem,'' ''verapamil,'' ''atenolol,'' and ''metoprolol,'' while ''ivabradine'' was used as a substance name. We also used a validated PubMed research methodology filter, 20 which is designed to retrieve scientifically strong studies of treatment, optimizing for a sensitive rather than a specific search.
Data collection and assessment of quality
All qualifying studies were assessed for adequate randomization, blinding, and completeness of followup. Data regarding detailed inclusion criteria, treatment type, and duration of follow-up were abstracted (as available) from each individual study.
Statistical analysis
Primary outcome was the change in resting HR at the study end attributable to the antianginal agent. To obtain this value, for parallel-design studies, we subtracted the resting HR in the placebo group from that in the treatment group. If the resting HRs at the study end were not available, then changes from baseline were compared between treatment and placebo (concerning 3 trials) groups. For crossover design trials, each treated group was considered separately: the resting HR at the end of the placebo control period was subtracted from that at the end of the drug treatment period.
Pooled estimates of the effect of antianginal drugs on resting HR were calculated through the use of weighted mean difference and fixed-effect meta-analysis. Standard errors (SEs) needed for the weight calculation were abstracted or, if not reported, derived from standard deviations (SDs), confidence interval (CIs), P values (if given with sufficient precision), or graphs.
Heterogeneity between studies was tested with the 2-based Q statistic and considered significant at P , 0.05. We also used the I 2 statistic, which is independent of the number of studies and quantifies heterogeneity on a scale of 0% to 100%. Very large heterogeneity between studies is usually denoted by I 2 values $75%.
For crossover design trials, the pooled variance for the net HR difference between the treated and control periods was calculated as follows:
where s t and s c are the SD of the treatment and control period HR values, respectively, and r is the withinindividual correlation between the treatment and control period HR values. To impute the SD of these differences, we used a r value for the correlation coefficient from another study in the meta-analysis. This imputation used crossover trials reporting simultaneously the between-period difference mean and SDs (or SEs) and the means and SDs (or SEs) for measurements on A and B separately. In this case, r can be estimated by the following formula:
On the basis of measured correlations in the ivabradine trials (the only trials for which we have access to individual patient data permitting this calculation), the within-individual correlation r between HR values was estimated to be 0.75 for crossover trials.
A sensitivity analysis was undertaken, testing different values of r to determine whether the overall result of the analysis is robust to the use of imputed correlation coefficients. Finally, the SE of the mean difference used by the meta-analysis calculation was obtained using the formula
In any single trial, when there were several arms, enabling more than 1 comparison, we weighted the number of participants so that each participant was used only once. For crossover trials with multiple (.2) periods, we assumed that the different experimental periods were independent, given that the deviation from this hypothesis only affects the overall estimations combining all doses of the same drug but not the dose-specific estimations.
To assess publication bias, a funnel plot of the treatment effect versus SE was visually inspected. All analyses were performed with R Statistical Software (R Development Core Team [2011] . R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria). Statistical significance was defined as 2-tailed alpha error ,0.05.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
RESULTS

Overview of trials
Of the 336 references screened, 23 studies fulfilled our inclusion criteria, but only 18 of the 23 trials (78%) reported resting HR data and were included in the final analysis ( Figure 1 ). In all, 8 trials were excluded. A list of the excluded trials, together with the reasons for their exclusion, is provided in the Supplemental Digital Content 1 (http://links.lww.com/AJT/A6).
Of the 18 trials included in this analysis, 10 assessed diltiazem, 3 verapamil, 4 atenolol, 4 metoprolol, and 2 ivabradine ( Table 1) . Some trials included more than 1 study drug, which accounts for the difference between the number of trials in our study and the number of trials in which individual drugs were employed. Seven trials included more than 1 treatment period or arm, with one placebo and several dosages of 1 or more of the drugs of interest, 3 had a parallel design, and 18 were crossover studies. The median study size was 20 patients (range, 10-728). In total, data from 1902 patients were available from these trials and were included in the meta-analysis (403 patients included in diltiazem trials, 93 in verapamil, 243 in atenolol, 75 in metoprolol, and 1088 in ivabradine trials). The mean age of the study populations ranged from 51 to 78 years.
Effects on HR
The pooled estimates for each drug are presented in Figure 2 , and the relationships between treatment effect and baseline HR (or HR on placebo) are presented in Figure 3 . Detailed Forest plots showing individual trial results are given in the Supplemental Digital Content 1 (http://links.lww.com/AJT/A6).
The reduction in resting HR for diltiazem versus placebo ranged from 20.08 bpm (95% CI, 21.5 to 1.4) for 120 mg/d to 28.0 bpm (95% CI, 211.1 to 25.0) for 360 mg/d. There was a considerable heterogeneity (I 2 = 74%) among the results of the 4 trials with 180 mg/d, without any clear explanation. Overall, diltiazem sustained release (SR) was associated with a reduction in resting HR of 24.5 bpm (95% CI, 26.4 to 22.5) without evidence of dose-response relationship (heterogeneity P = 0.62, I 2 = 0%). The other calcium channel blocker, verapamil, reduced resting HR by 23.2 bpm (95% CI, 25.1 to 21.3) when all doses were pooled. No dose-response relationship was found (heterogeneity P = 0.87, I 2 = 0%). Only 2 of the eligible studies with the beta-blocker atenolol provided data on resting HR, 34, 36 which together gave a resting HR reduction of 219.0 bpm (95% CI, 220.4 to 217.6) for atenolol 100 mg/d. Overall, the reduction obtained with metoprolol was 213.2 bpm (95% CI, 214.7 to 211.7) with a clear dose-response relationship (heterogeneity P = 0.08, I 2 = 53%); the greatest HR reduction was reported with the highest doses [metoprolol tartrate 150 mg/d and metoprolol OROS (oral osmotic, ie, long acting) 190 mg/d].
Overall, the I f inhibitor ivabradine induced a 12.4 bpm reduction in resting HR (range, 213.7 to 211.0 bpm). A clear dose-response relationship was apparent (heterogeneity between dose subgroups P , 0.001) and ivabradine-induced resting HR reduction ranged from 29.3 bpm (average) with 2.5 mg 2 times a day to 219.6 bpm (average) with 10 mg 2 times a day.
We found no consistent visual or statistical evidence of publication bias (ie, a tendency for small studies to be more likely to be published if they have significant positive results). In sensitivity analysis, the use of 0.5 as r value was associated with statistically significant variations but did not substantially affect the point estimates.
DISCUSSION
Our data indicate a considerable variation in the magnitude of the reduction in resting HR with the most frequently employed antianginal and anti-ischemic drugs in patients with stable CAD at the doses most commonly used clinically (and, indeed, throughout the recommended dose range for these agents). The most predictable and largest reductions were seen with the beta-blockers, atenolol and metoprolol, and the I f inhibitor ivabradine. These agents were also unique in revealing clear dose-response relationships for HR reduction. The HR reductions with the beta-blockers and ivabradine appear to be related to the HR at baseline, with greater efficacy in reducing HR at higher baseline values.
The HR-reducing effect of these antianginal agents is predictable from their pharmacological profile. The beta-blockers inhibit the effect of beta-adrenergic agonists on the beta-receptors. In this way, betablockers reduce the activation of G proteins, which reduces levels of intracellular cyclic adenosine monophosphate (cAMP). In turn, this modulates the activity of L-type calcium channels (inward current) and potassium channels (outward current) in the sinoatrial node. These channels are responsible for spontaneous depolarization and therefore help define HR. The betareceptors also affect the activity of the f channels via their effect on cAMP, which modulates the I f current and therefore the rate of the slow (diastolic) depolarization. In addition, beta-blockers have other actions that may affect HR, for example, coronary vasoconstriction and an impact on atrioventricular node function. The L-type calcium channel blockers verapamil and diltiazem also feature pharmacological effects that slow HR. Indeed, these are believed to contribute to their antianginal effects, particularly in the case of verapamil. 44 The mechanisms underlying HR slowing here include the blockade of the inward Ca current, which slows depolarization and propagation of the action potential. 45 However, at doses employed clinically, these drugs also have prominent effects on blood pressure (directly causing vasodilatation, possibly mitigating their direct effects on HR) and atrioventricular node function, which is an effect that is greater than their effect on the sinoatrial node. 46 As opposed to other HR-reducing agents, ivabradine has high specificity and selectivity for its target, the f-channel: the drug inhibits the f channel by an interaction that requires the presence of cAMP and is itself modulated by the polarization status of the sinoatrial node cell. Thus, ivabradine minimizes the current and modulates the slow diastolic depolarization, slowing HR directly. 47 HR plays an important role in the pathophysiology of ischemic heart disease. 48 A regression analysis in patients with angina has shown that anti-ischemic efficacy is directly related to efficacy in reducing resting HR. 49 Moreover, in patients with stable CAD, HR reduction is directly related to reduction in frequency of anginal attacks. 42 We focused on HR recorded during studies that were performed primarily to assess drug antianginal efficacy but not effects on HR. The doses were selected for antianginal efficacy, and it is unlikely that dose selection bias has affected our results. In addition, we analyzed impact on resting HR; however, angina generally occurs during exercise, when HR is higher and myocardial oxygen consumption is greater. The clinical importance of resting HR reduction may be particularly relevant during exercise. In all the studies we selected, the effects on peak exercise HR have been found to parallel the effects on resting HR. 42 Although HR slowing during exercise is important in the prevention of angina pectoris, 50 other effects of reduction in resting HR may also have an impact on long-term outcomes. Thus, epidemiological studies involving more than 100,000 persons, 51 with follow-up as long as 36 years, indicate that resting HR is inversely related to all-cause mortality. For example, relatively 
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American Journal of Therapeutics (2012) 19 (4) high resting HR (.75 bpm) was associated with excess mortality in men. 52, 53 Cardiovascular mortality and major cardiovascular morbidity rates also appear to be directly related to resting HR. 51, 53 The Framingham Heart Study followed a cohort of 5209 men and women for 30 years; all-cause and cardiovascular mortality increased progressively in association with resting HR in both men and women older than 35 years, although the risk was significantly higher in men. 3 A recent study including more than 5000 men aged 42-53 years found that subjects with resting HR .75 bpm had an increased risk of sudden death during a 23-year follow-up period (relative risk 3.92 versus 1.00 for HR,60 bpm). 54 Perhaps, most importantly in the context of antianginal agents, data on patients with chronic stable CAD have demonstrated the direct relation of resting HR to subsequent outcome. 4, 5 For example, Shaper et al 55 studied the relationship between resting HR and the emergence of major ischemic heart disease events in a sample of middle-aged men American Journal of Therapeutics (2012) 19(4) www.americantherapeutics.com (n = 7735) with and without preexisting heart disease.
The study reported 8 years of follow-up for cardiovascular morbidity and mortality. Elevated HR was reported to be an independent risk factor for CAD mortality in this population. The Coronary Artery Surgery Study explored the relationship between resting HR measured at baseline and cardiovascular outcomes in more than 24,000 patients over 24 years. 4 The authors constructed a multivariate risk model of the outcome and established the independent effect of HR on cardiovascular mortality and morbidity. Relative to HR ,77 bpm, values between 77 and 82 bpm resulted in a hazard ratio of 1.16 (range, 1.04-1.28) and values .83 bpm a hazard ratio of 1.32 (range, 1.19-1.47). The BEAUTIFUL investigators brought further confirmation of this relationship in their prospective analysis of the effect of resting HR at baseline on outcomes in the placebo arm of the trial. 17 Patients with HR $70 bpm were at an increased risk of cardiovascular outcomes, including cardiovascular mortality (34%; P = 0.0041) and HF (53%; P , 0.0001), and coronary outcomes, such as MI (46%; P = 0.0066) and coronary revascularization (38%; P = 0.037), compared with those whose HR was ,70 bpm. Notably, the BEAUTIFUL population was particularly well treated in terms of cardiovascular prevention and 87% of the placebo group were receiving beta-blocker. 18 Resting HR is therefore a well-established risk marker for cardiovascular mortality and major adverse cardiovascular events. Additional data suggest that it is also a risk factor, that is, that its downward modulation by active therapy beneficially affects the outcome in patients with CAD. 48 Our previous meta-regression analysis is consistent with this proposal because we found that the beneficial effects of beta-blockers and calcium channel blockers in post-MI patients are proportional to those in resting HR, 56 which is also in line with earlier studies. 57 Also, a recent analysis by Jouven et al 58 reported that healthy subjects whose resting HR decreased by .4 bpm over 5 years had 14% lower risk of mortality versus those whose HR increased by .3 bpm.
These observations were confirmed prospectively in the BEAUTIFUL study, which demonstrated the benefits of pharmacological reduction of HR $70 bpm with ivabradine in patients with stable CAD and left ventricular dysfunction, in terms of a reduction in risk of coronary events [36% reduction in MI (hazard ratio, 0.64; 95% CI, 0.49-0.84; P = 0.001) and 30% reduction in coronary revascularization (hazard ratio, 0.70; 95% CI, 0.52-0.93; P = 0.016)]. 18 This constituted the first evidence of a relationship between reduction in HR and an improvement in outcomes in stable CAD. There is no direct evidence for this effect with betablockers in stable CAD patients, although there is evidence in post-MI and heart failure patients. 56, 57 The pharmacological reduction of HR should therefore be viewed as a primary strategy in the management of patients with stable CAD, and one that is likely to improve outcomes. The data from our study suggest that such strategies are likely to produce greater HR reductions if they involve beta-blockers and/or ivabradine, than if they involve HR-slowing calcium channel blockers alone.
Only 1 trial used a SR of diltiazem. 30 Therefore, data are insufficient to formally compare immediate release and sustained release forms. Moreover, diltiazem SR 200 and 300 mg gave similar reduction in rest HR, 24 and 25 bpm, respectively. These reductions are nominally greater than those observed with the low dose (120-240 mg) immediate release (between 0 and 1.6 bpm). High dose (360 mg) immediate release gave a much bigger reduction (8 bpm) in HR than the SR. However, the small number of trials limits conclusions.
Several methodological aspects of our meta-analysis deserve further consideration. We aimed to minimize publication bias through an exhaustive search of the available literature by searching in multiple databases (Medline, Embase, and the Cochrane Controlled Trials Register) and by checking references in selected publications.
We used summarized patient data extracted from the publication and not individual patient data. Although patient level data might have been preferable, most trials are quite old, precluding obtaining the data files. Individual patient data would have allowed some trial reanalysis and standardization, enabling inclusion of more trials in the meta-analysis. Despite this limitation, statistical methods used with summarized data give the same average results quantitatively as individual patient level data.
This meta-analysis used absolute HR reduction as its end point. Relative reduction from baseline may be more useful because it accounts for the initial HR. A higher absolute reduction in HR is more likely if initial resting HR is high. 59, 60 However, data allowing calculation of the relative changes were not regularly reported in the publications on which the meta-analysis was based. Indeed, baseline HR was often not reported, which meant that it was impossible to adjust for baseline HR; this may have resulted in heterogeneity in our findings. Another potential limitation is that the reduction of the rate-pressure product may be considered to be a better indicator of antianginal efficacy than HR alone. Unfortunately, rate-pressure product data were available for only 4 of the trials presented here, which reduce the power of any such analysis.
A further potential limitation was the need to impute a r correlation coefficient for the metaanalysis. Almost all the studies used crossover designs and did not report the variance of between-period differences. Therefore, we needed to impute this value. To minimize the effect of this procedure, we used a conservative imputation value, minimizing the treatment effect. This arbitrary choice may have precluded detection of statistically significant differences in some cases but should have little effect on the magnitude of point estimates of a treatment effect. Despite this, the estimations given by the metaanalysis appeared robust in sensitivity analysis. Moreover, given that most of the studies were crossover and required imputation of variance using our method of choice, a change in the imputed variable implied the same change in almost all studies; therefore, the relative weights of the studies remain unchanged by use of the imputation.
CONCLUSIONS
In this meta-analysis of prospective, randomized, double-blind, placebo-controlled clinical trials, ivabradine, atenolol, and metoprolol reduced resting HR by approximately 10-20 bpm in patients with stable angina pectoris. The reductions obtained with diltiazem and verapamil were smaller, generally less than 10 bpm. Our analysis was confined to doses commonly employed clinically and believed to be of equivalent antianginal efficacy. Given the probable benefits of HR reduction for improvement in the natural course of disease among patients with CAD (demonstrated with ivabradine, although not studied in stable CAD with the other drugs), consideration of our data may be useful in the selection of antianginal agents for patients with stable angina pectoris.
